CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
calcium aluminosilicate anti-diarrheal +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00748215
NCT00748215Phase 2Completed
CompareCT.gov

Phase II, Randomized, Double Blind Comparison of CASAD vs. Placebo for the Treatment and Prevention of Diarrhea in Patients With Metastatic Colorectal Cancer

M.D. Anderson Cancer Center·interventional·Posted Sep 8, 2008·Updated Dec 2, 2020

In Brief

A Phase 2 clinical trial evaluating calcium aluminosilicate anti-diarrheal and placebo for Chemotherapeutic Agent Toxicity and 2 related conditions. Completed, enrolled 100 participants across 2 sites.

Detailed Summary

RATIONALE: Calcium aluminosilicate anti-diarrheal (CASAD) may help treat and prevent diarrhea caused by irinotecan. It is not yet known whether CASAD is more effective than a placebo in treating and preventing diarrhea in patients receiving irinotecan. PURPOSE: This randomized phase II trial is studying CASAD to see how well it works compared with a placebo in treating and preventing diarrhea in patients with metastatic colorectal cancer receiving irinotecan.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChemotherapeutic Agent Toxicity, Colorectal Cancer, Diarrhea
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 8, 2008
Enrollment StartFeb 4, 2009
Primary CompletionAug 12, 2014
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 17.8 years ago

Interventions

calcium aluminosilicate anti-diarrhealdrug

Given orally

placeboother

Given orally